Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | PARG | Q86W56 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 5/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26093223 | 0.86 | CA1 (0.46) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL23557731 | 0.81 | LMNA (0.56) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL29875355 | 0.79 | F12 (0.48) | CA1CA2MAP3K14CDC7CDK2 | |
| SCHEMBL25255763 | 0.79 | CA2 (0.42) | CA1CA2MAP3K14CDC7CDK2 | |
| SCHEMBL6436605 | 0.79 | F12 (0.48) | CA1CA2MAP3K14CDC7CDK2 | |
| SCHEMBL17861412 | 0.79 | CYP2A6 (0.48) | CA1CA2MAP3K14CDC7CDK2 | |
| SCHEMBL13037655 | 0.76 | CA2 (0.57) | CA1CA2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1317870 | 0.75 | LMNA (0.50) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL29786977 | 0.75 | LMNA (0.50) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL26317711 | 0.75 | DRD1 (0.46) | CYP3A4MAPTCA1CA2MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-3233827-B1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | ACRAF (IT) | 2020-07-08 | — | — | EP | disclosed |
| US-10221144-B2 | Antibacterial compounds having broad spectrum of activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-20170369450-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-28 | — | — | US | disclosed |
| EP-3233827-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096686-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| EP-1023268-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369450-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | MRPL21, ABCG2, CLPP | LMNA 3897/4885CYP3A4 1704/4885MAPT 3361/4885 |
| US-10221144-B2 | Antibacterial compounds having broad spectrum of activity | MRPL21, ABCG2, CLPP | LMNA 3897/4885CYP3A4 1704/4885MAPT 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.